Global Urothelial Cancer Drugs Market to Reach $15.3 Billion by 2030
The global market for Urothelial Cancer Drugs estimated at US$2.4 Billion in the year 2022, is projected to reach a revised size of US$15.3 Billion by 2030, growing at a CAGR of 26.3% over the analysis period 2022-2030. Immunotherapy, one of the segments analyzed in the report, is projected to record 25.7% CAGR and reach US$12 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Chemotherapy segment is readjusted to a revised 28.6% CAGR for the next 8-year period.The U.S. Market is Estimated at $693.3 Million, While China is Forecast to Grow at 25.5% CAGR
The Urothelial Cancer Drugs market in the U.S. is estimated at US$693.3 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 25.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 23% and 21.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 17.6% CAGR.Select Competitors (Total 42 Featured) -
- AstraZeneca
- Bristol-Myers Squibb
- Celgene Corporation
- Eli Lilly and Co.
- Exelixis, Inc
- Genentech
- GlaxoSmithKline
- Merck
- Novartis International AG
- Pfizer
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
REST OF EUROPE
ASIA-PACIFIC
REST OF WORLD
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca
- Bristol-Myers Squibb
- Celgene Corporation
- Eli Lilly and Co.
- Exelixis, Inc
- Genentech
- GlaxoSmithKline
- Merck
- Novartis International AG
- Pfizer
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 93 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 2.4 Billion |
Forecasted Market Value ( USD | $ 15.3 Billion |
Compound Annual Growth Rate | 26.1% |
Regions Covered | Global |